ImmuPharma (LON:IMM) Trading Up 18.6% - Should You Buy?

Key Points

• ImmuPharma's stock surged by 18.6% to GBX 12.87 during mid-day trading, significantly increasing trading volume by 198% compared to the average daily volume.
• The company has a market capitalization of £64.31 million, with a reported price-to-earnings ratio of -1,446.07, indicating negative earnings performance.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases and has a lead program, Lupuzor™, targeting Lupus treatment.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was up 18.6% during mid-day trading on Friday . The company traded as high as GBX 13.45 ($0.18) and last traded at GBX 12.87 ($0.17). Approximately 23,818,584 shares changed hands during trading, an increase of 198% from the average daily volume of 8,001,320 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Up 18.6%

The company has a market capitalization of £64.31 million, a price-to-earnings ratio of -1,446.07 and a beta of 1.53. The business has a 50-day moving average price of GBX 2.88 and a 200-day moving average price of GBX 2.86.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, sell-side analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.